Gemcitabine: A Review of its Use in the Management of Pancreatic Cancer

Author： Frampton James E. Wagstaff Antona J.

ISSN： 1175-6357

Source： American Journal of Cancer, Vol.4, Iss.6, 2005-01, pp. : 395-416

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Uptake and Patterns of Use of Gemcitabine for Metastatic Pancreatic Cancer: A Population-Based Study

By Oberstein Paul E. Hershman Dawn L.

Cancer Investigation, Vol. 31, Iss. 5, 2013-06 ,pp. : 316-322

Informa Healthcare

Access to resources Recommend Favorite

Erlotinib or capecitabine with gemcitabine in pancreatic cancer?

By de Jager Jenny Stebbing Justin

Future Oncology, Vol. 2, Iss. 2, 2006-04 ,pp. : 161-163

Future Medicine

Access to resources Recommend Favorite

Pancreatic cancer – cost for overtreatment with gemcitabine

By Ansari Daniel Tingstedt Bobby Andersson Roland

Acta Oncologica, Vol. 52, Iss. 6, 2013-08 ,pp. : 1146-1151

Informa Healthcare

Access to resources Recommend Favorite

Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer

By de Lange S.M. van Groeningen C.J. Meijer O.W.M. Cuesta M.A. Langendijk J.A. van Riel J.M.G.H. Pinedo H.M. Peters G.J. Meijer S. Slotman B.J. Giaccone G.

European Journal of Cancer, Vol. 38, Iss. 9, 2002-06 ,pp. : 1212-1217

Elsevier

Access to resources Recommend Favorite

Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer

Oncology Letters, Vol. 4, Iss. 4, 2012-01 ,pp. : 792-798

Spandidos Publications

Access to resources Recommend Favorite